Introduction
Chronic obstructive pulmonary disease (COPD) currently accounts for an estimated 15-20% of all hospital admissions in the UK, 1 and acute hypercapnic respiratory failure (AHRF) complicates up to 20% of episodes. Of these, approximately 80% receive noninvasive ventilation (NIV) during their hospital admission. 2 A systematic review based on several randomized controlled trials provided evidence that, when used in COPD, NIV decreased mortality, the need for intubation, and treatment failure. 3 Moreover, NIV increased pH, reduced hypercapnia and the respiratory rate within 1 h of its institution, shortened the length of hospital stay by more than 3 days and decreased complications associated with treatment. 4 We review the situation where NIV is deemed the 'ceiling of treatment' and patients do not proceed to 'invasive' ventilation. We also review the use of advanced directives and the implications of the Mental Capacity Act 2005 (MCA) on decisions regarding end-of-life care.
In AHRF with severe acidosis (pH <7.25) invasive ventilation is advocated by guidelines, 5 but clinicians may trial NIV initially. NIV may also be provided for patients with less severe acidosis (typically pH 7.25-7.35) without contraindications, or in patients who fulfill criteria for invasive ventilation but where it is not suitable.
Published rates of survival to hospital discharge for patients with respiratory failure caused by COPD and a do-not-intubate order who received NIV are perhaps surprisingly good, but based on small numbers of patients. A recent prospective American study with 24 patients had a 63% chance of survival to hospital discharge. 6 Similarly, hospital survival of 51% was found in a study of 34 patients. 7 NIV failing after being used for more than 48 h also include not only a low pH but also a low ADL score (activities of daily living). Neither age nor Acute Physiology and Chronic Health Evaluation (APACHE) II score are predictive of failure. 9 Others have suggested that a score based on the Simplified Acute Physiology Score (SAPS) II and serum albumin level is predictive of hospital outcome. 10 Alternatively, it has been suggested that being awake and having a strong cough are markers of good prognosis. 7 A recent comprehensive review has concluded that at present no clinical characteristics can reliably distinguish, which patients with COPD will benefit from life-supportive care and which will unnecessarily suffer a prolonged death. 11
Withholding invasive ventilation in AHRF in COPD
The decision regarding the use of 'invasive' ventilation in a patient with an exacerbation of COPD is challenging. A major component of the challenge is predicting if the potential benefit outweighs the risk. It is under-appreciated that COPD patients admitted to the intensive care unit (ICU) in the UK have a mortality of 23% in the ICU and 38% in hospital, which is similar to the mortality of patients with all diagnoses admitted to ICU. 12 However, patients entering ICU will represent a selected group of all those patients admitted to hospital with AHRF caused by COPD. Patients with 'end-stage' COPD, particularly those with severe functional limitation, are often not admitted to a critical care environment.
In some parts of the world (North America in particular) patients who are having a prolonged respiratory wean are transferred from the ICU to a long-term care hospital (LTCH). Of these, a large proportion has COPD as their underlying diagnosis. 13 Patients in these units have low chance of survival 14 and a depressingly slim chance of leaving the LTCH with a good functional status. 15 It could be argued that a large proportion of these patients represent those who should not have been offered invasive ventilation initially.
In 1987, Pearlman 16 described how estimates of survival for the same patient with acute respiratory failure caused by COPD vary between physicians (ranging from 1 month to 5 years). Similarly, a study by Wildman, et al. 17 in 2003 concluded that consultants differed markedly in their decisions regarding admission to intensive care for identical patients. Clinicians are generally pessimistic about the survival prospects of patients with exacerbations of COPD and have particular problems in identifying those with poor prognosis. 18 Defining 'end-stage' COPD The nature of COPD, with its gradual decline punctuated by episodic exacerbations, does not lend itself to accurate prognostication. Characteristics of patients usually considered to have 'end-stage' COPD would include very severe airflow limitation (FEV 1 <30% predicted) with markedly limited and declining performance status, and perhaps also with one of: advanced age, multiple co-morbidities and severe manifestations/complications of COPD. 11 In the first phase of SUPPORT (Study to Understand Prognosis and Preferences for Outcomes and Treatments), a prognostic model was established that has equal discrimination and slightly improved calibration compared with physicians' estimates of survival. 19 This predictive model was applied to patients with severe COPD and lung cancer, and the estimated chance of 6-month survival was repeatedly calculated during their hospital admission. Among patients who died, the calculated 6-month mortality in the last week of their life was 20% for patients with lung cancer, but 40% or greater in those with COPD, 20 i.e. even in patients with advanced COPD, who are later found to have been in their last week of life, their physicians estimated a good chance (over 40%) of surviving 6 months during that final week.
Is palliative NIV justified?
The SUPPORT study concluded that in patients with severe COPD, consideration should be given to implementing palliative treatments more aggressively, while remaining open to provision of lifesustaining interventions. Despite maximal medical therapy, patients with advanced COPD often remain highly symptomatic. In comparison to patients with similar levels of symptoms, but due to lung cancer, there is evidence that patients with COPD do not receive palliative care either as frequently or of the same quality. 21 The use of NIV in patients with a do-not-intubate order and acute respiratory failure is not without controversy. Some authors believe that it may be providing a form of life support for patients who do not desire it and perhaps adds to discomfort and potentially prolongs the dying process. 22 Provided the patient is obtaining symptomatic benefit and wishes to continue using NIV, this concern can to a large extent be put aside. As previously discussed, it is not simple to ascertain who is 'terminal', and more than half these patients will survive to hospital discharge.
In the absence of information to the contrary, when confronted with a patient with COPD and AHRF, the default position is to provide NIV pending further information (once standard medical management has been instituted). NIV can 'buy time' to find out further information, and allow time to clarify the appropriate limits (if any) to the patient's care. NIV may also allow time to arrange affairs and allow closure for patients and relatives. 23 Without defining goals, it is difficult to know whether treatment with NIV has succeeded or failed.
Breathlessness can be extremely distressing during COPD exacerbations and NIV provides rapid relief of breathlessness. 24 Furthermore, exhausted patients are often able to sleep once anxiety and work-of breathing are relieved. 23 Symptoms of hypercapnia, such as confusion or headaches, may also be relieved. NIV has even been used as a palliative treatment for breathlessness in patients with end-stage cancer. 25 A European Respiratory Society Task Force has recently published a survey of end-of-life decisionmaking in respiratory intermediate care units in Europe. 26 A questionnaire was sent to 95 European respiratory care units. Only 28 (30%) replied (including two units in Britain). Over a 6-month period, an 'end-of life' decision was made in 22% of 6008 patients. These patients were categorized in broadly similar rates as 'withholding of treatment', 'do not resuscitate orders', and 'NIV as ceiling of ventilatory care'. In the latter group, 158 of 402 patients (39%) received NIV as a palliative care strategy, usually to reduce dyspnea. Interestingly, <40% of patients were described as having participated in decision-making.
Communication
Prior to starting NIV, it is unlikely that patientclinician communication about palliative and endof-life care is likely to have occurred. 27 It is unfortunate that advance directives are uncommon 28 as they increase patient autonomy and patients educated in advanced directives are more likely to be assured that their physicians will understand their preferences. 29 Patients with 'end-stage' COPD will raise these issues if prompted to do so. 30 Unlike the situation in lung cancer where deterioration tends to be progressive, in severe COPD there may be relative stability, punctuated by exacerbations, any of which might be fatal. In COPD 'active' and 'palliative' treatments can coexist, and this along with other barriers makes discussion about death and dying difficult.
Patients have the right to refuse NIV, even if doctors think that it is in their best interest. In Britain, the MCA codifies the right of legally competent adults to refuse life-sustaining treatment, provided that they possess 'capacity'. 31 Where patients lack capacity, interventions must be in their 'best interests'. It is rare for patients to have made 'living wills' [referred to as advanced decisions (AD) in the MCA], but where there are known beliefs or values it is important to take account of these. It must be recognized that 'quality of life' is a very subjective judgment, and all efforts should be made to ascertain the patient's own views. Where patients have had time to adapt to disability they may well rate their quality of life as good, whereas to an outside observer it might not seem so. Conversely, some patients with end-stage COPD will freely admit that their life is intolerable and they desire no more than conservative management.
When the patient does not have capacity and an important decision regarding a patient's health care needs to be made (such as instituting or discontinuing NIV), the MCA places a legal obligation on us to seek the opinion of all parties who have an interest in the patient's wellbeing. This will include relatives and formal carers but may also include friends and neighbors. We are under no obligation to adhere to the opinions of these persons except in one circumstance. The predetermined lasting power of attorney (LPA), or surrogate, can make decisions on an incompetent patient's behalf that can include the ability to refuse life-sustaining treatment if the document appointing the LPA explicitly acknowledges this. Because the MCA is statutory law, it is a criminal offence to ignore the AD or the LPA. 32 Where a patient with severe COPD makes an AD that they do not wish to receive NIV or would like NIV as the ceiling of treatment, the physician can respect that choice. Similarly, the situation is relatively straightforward if the patient and clinician both agree that invasive ventilation is appropriate. Ethically, a doctor is not obliged to provide a treatment they perceive as futile, even if the patient requests it. The rationing of scarce critical care beds and judgments concerning cost-benefit and distributive justice are also factors to be taken into consideration.
Practical aspects of NIV
Although not all district general hospitals in Britain have high dependency units or respiratory wards, NIV can be delivered safely on medical wards, given appropriately trained staff. 24 Staff training and experience are more important than location, but adequate numbers of staff skilled in NIV must be available throughout the 24-h period. There are no data comparing intensivist-led to respiratory physician-led NIV services; they each have their pros and cons. Every hospital will have developed its NIV service differently dependent upon existent resources and the specialist interests of its staff. The practical aspects of starting NIV and the 'troubleshooting' aspects are beyond the scope of this review and are well covered elsewhere. 33 It is common for patients in acute respiratory failure to have either impaired consciousness or cognition and assessing their capacity to consent to NIV is difficult. It is not unusual for the patient to be agitated and distressed, and the introduction of a face mask may be met with resistance. Those caring for the patient should persevere. However, if it becomes clear that the NIV is causing the patient distress, it should be discontinued unless there is a genuine belief that the patient lacks capacity, and is objectively benefiting from the NIV. In these difficult circumstances, it is crucial that the patient's relatives have a good understanding of what is occurring and why.
Stopping NIV
Despite the use of NIV, patients may not experience improvement in their ventilatory failure, either symptomatically, or as assessed biochemically (arterial blood gas analysis) or physiologically (respiratory and heart rate). If the patient is a candidate for invasive ventilation then intensive care should be urgently consulted. If when NIV is to be the ceiling of treatment and once NIV has been maximally optimized, comfort becomes paramount.
Members of the multi-disciplinary team including ward nursing staff, physiotherapists and specialist nurses will all be able to contribute to assessment of symptomatic improvement and should, therefore, be involved in the decision-making.
If the patient is tolerating the NIV, but showing no early signs of improvement, then the NIV can be continued and the response reassessed a few hours later. If there remains no physiological or biochemical improvement but the patient is symptomatically improved, then it is reasonable to continue and in this context NIV may be considered as an effective palliative measure. 20 Conversely, if the patient feels no benefit then it should be stopped.
Patients with AHRF caused by COPD who have been unable or unwilling to tolerate NIV vary in their level of alertness and distress. Symptoms including breathlessness, sleeplessness, anxiety, pain, and exhaustion may be very distressing. If progressive hypercapnia develops, they may become gradually less alert and this may relieve some distress.
On one extreme, the treating physician may feel that all medical treatment should be withdrawn that is not improving the patient's symptoms. Priority is for comfort, perhaps at the expense of best chance of recovery. Conversely, the treating physician may want to give all treatments that may potentially allow the patient to recover from this episode without risking giving any treatments such as sedation that may compromise this goal. We advocate an approach where chance of successful outcome is maximized but with attention to treating distressing symptoms.
Management after discontinuation of NIV
Medical therapy should be optimized, but with a low threshold for stopping treatments if they are causing side effects. Non-pharmacological measures can be of great value and include providing good air movement near the patient (e.g. a fan), keeping cool room temperatures, and measures to minimize the patient's exertion or anxiety. Anxiety and emotional distress are closely linked with the experience of breathlessness, the dyspnea-anxiety-dyspnea cycle. 34 A systematic review has shown a beneficial effect of opioids on the sensation of breathlessness. 35 Oral or parenteral opioids were found to be better than nebulized opioids. Low-dose sustained release morphine improves dyspnea, quality of sleep, wellbeing, and performance on physical exertion in patients with breathlessness despite maximally treated COPD. 36 Well-recognized side effects such as drowsiness, nausea, vomiting, dizziness and constipation can, to some extent, be anticipated and treated. The possible mechanisms of action of opioids include reduction in the central perception of dyspnea, reduc-tion in anxiety associated with dyspnea, reduction in sensitivity to hypercapnia, reduction in oxygen consumption, and improved cardiovascular function. There have been no recent studies on the role of benzodiazepines in the relief of dyspnea in COPD. 37 However, they are commonly added to the opioid regimen to alleviate the anxiety that may be associated with breathlessness. Many clinicians will start a low-dose subcutaneous infusion of opioid and/or benzodiazepine before removing the NIV mask, least symptoms deteriorate.
The widely accepted principle of 'double effect' permits the relief of suffering as the primary intention despite the fact that life may inadvertently be shortened as a result. Sedating drugs might be expected to depress ventilatory drive, worsen hypercapnia and accelerate death, but there is little evidence to suggest that the cautious administration of opioids or benzodiazepines in this context does hasten death. In terminal withdrawal of ventilation on the ICU, there is evidence that these drugs do not hasten death. 38 If unconsciousness develops then retained respiratory tract secretions can cause noisy breathing that may be distressing for relatives and can be treated with anticholinergic agents and cautious use of airway suctioning. As death approaches, the use of subcutaneous infusion of morphine (or diamorphine) and/or midazolam can help terminal breathlessness and anxiety. It is important to explain to relatives that the aim is not to shorten life but to provide the lowest dose of drug necessary to relieve distressing symptoms. Table 1 lists some of the drugs that can be useful in controlling symptoms in terminal COPD.
Resuscitation
If NIV fails and a patient is 'not for invasive ventilation', this is tantamount to a 'do not resuscitate' decision. Guidelines have been produced regarding cardiopulmonary resuscitation (CPR) for people who are terminally ill. 39 CPR is not appropriate if there is virtually no chance of CPR re-establishing cardiopulmonary function, would result in a quality of life unacceptable to the patient, or is contrary to the competent patient's expressed wishes. Decisions regarding resuscitation status should be multidisciplinary and appropriately documented.
Research priorities
A research priority is improving prognostication in individuals with acute exacerbations to facilitate decision-making regarding appropriate level of care. Improved patient-physician communication and the use of advanced directives should improve patient autonomy and increase concordance between the wishes of the patient and their families and the treating clinicians. Use of NIV as a palliative measure in AHRF caused by COPD is widespread, but lacking good evidence. Similarly, there are little published data on the safety and economic evaluation of different sites for delivering NIV (e.g. ICU vs. respiratory HDU vs. medical wards). Given the widespread concerns about concurrent use of potentially sedating therapies (benzodiazepines and opiates) with 'active' treatment, systematic prospective collection of data regarding adverse effects, symptom burden and clinical outcome is advocated.
Conclusion
Despite advances in treatment for acute respiratory failure in COPD, including NIV, there remains inadequate relief of distressing symptoms in the final stages of the disease. Chance of successful outcome should be maximized whilst simultaneously providing effective palliative care.
In addition to improving survival, NIV can offer symptomatic benefit and be an effective palliative measure in 'end-stage' COPD during a hypercapnic exacerbation. Communication between the multidisciplinary team, patient and family is crucial throughout. 
